Omeprazole - CAS 73590-58-6
Catalog number:
B0084-294483
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C17H19N3O3S
Molecular Weight:
345.42
COA:
Inquire
Targets:
Proton Pump
Description:
Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase) and inhibits its activity and the parietal cell secretion of H+ ions into the gastric lumen.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-294483 25 g $188 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
proton pump inhibitor, dyspepsia
Purity:
>98%
Appearance:
White to off-white crystalline powder
Synonyms:
OPC-13013; Losec; Prilosec; Antra; Omeprazon
Solubility:
35.4 ug/mL
MSDS:
Inquire
Application:
the treatment of dyspepsia
Melting Point:
155 °C
InChIKey:
SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI:
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
Canonical SMILES:
CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
1.Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Gan L1, Jiang X2, Mendonza A1, Swan T1, Reynolds C2, Nguyen J2, Pal P3, Neelakantham S3, Dahlke M4, Langenickel T4, Rajman I4, Akahori M5, Zhou W2, Rebello S2, Sunkara G2. Clin Pharmacol Drug Dev. 2016 Jan;5(1):27-39. doi: 10.1002/cpdd.181. Epub 2015 Nov 4.
LCZ696 is a novel angiotensin receptor neprilysin inhibitor in development for the treatment of cardiovascular diseases. Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q.d.]) when co-administered with omeprazole 40 mg q.d. (n = 28) or metformin 1000 mg q.d. (n = 27) or levonorgestrel-ethinyl estradiol 150/30 μg single dose (n = 24) in three separate open-label, single-sequence studies in healthy subjects. Pharmacokinetic parameters of LCZ696 analytes (sacubitril, LBQ657, and valsartan), metformin, and levonorgestrel-ethinyl estradiol were assessed. Omeprazole did not alter the AUCinf of sacubitril and pharmacokinetics of LBQ657; however, 7% decrease in the Cmax of sacubitril, and 11% and 13% decreases in AUCinf and Cmax of valsartan were observed. Co-administration of LCZ696 with metformin had no significant effect on the pharmacokinetics of LBQ657 and valsartan; however, AUCtau,ss and Cmax,ss of metformin were decreased by 23%.
2.Interactions of omeprazole-based analogues with cytochrome P450 2C19: a computational study.
Li J1, Du H1, Wu Z1, Su H1, Liu G1, Tang Y1, Li W1. Mol Biosyst. 2016 Apr 21. [Epub ahead of print]
Cytochrome P450 2C19 (CYP2C19) is one of 57 drug metabolizing enzymes in humans and is responsible for the metabolism of ∼7-10% of drugs in clinical use. Recently omeprazole-based analogues were reported to be the potent inhibitors of CYP2C19 and have the potential to be used as the tool compounds for studying the substrate selectivity of CYP2C19. However, the binding modes of these compounds with CYP2C19 remain to be elucidated. In this study, a combination of molecular docking, molecular dynamics (MD), and MM/GBSA calculations was employed to systematically investigate the interactions between these compounds and CYP2C19. The binding modes of these analogues were analyzed in detail. The results indicated that the inclusion of explicit active site water molecules could improve binding energy prediction when the water molecules formed a hydrogen bonding network between the ligand and protein. We also found that the effect of active site water molecules on binding free energy prediction was dependent on the ligand binding modes.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products


Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

CAS 161796-78-7 Esomeprazole Sodium

Esomeprazole Sodium
(CAS: 161796-78-7)

Esomeprazole sodium (Nexium) suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell.

CAS 135779-82-7 Bamaquimast

Bamaquimast
(CAS: 135779-82-7)

Bamaquimast is an orally active inhibitor of proton pump with anti-inflammatory and antiasthmatic effects.

CAS 138786-67-1 Pantoprazole sodium

Pantoprazole sodium
(CAS: 138786-67-1)

The sodium salt form of Pantoprazole, a gastic proton pump inhibitor, could be used in the treatment of ulceration and some diseases induced by gastroesophageal...

CAS 161796-84-5 Esomeprazole potassium

Esomeprazole potassium
(CAS: 161796-84-5)

Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorat...

CAS 103577-45-3 Lansoprazole.

Lansoprazole.
(CAS: 103577-45-3)

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

CAS 138530-94-6 Dexlansoprazole

Dexlansoprazole
(CAS: 138530-94-6)

Dexlansoprazole is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux dis...

CAS 102625-70-7 Pantoprazole

Pantoprazole
(CAS: 102625-70-7)

Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in g...

CAS 117976-89-3 Rabeprazole

Rabeprazole
(CAS: 117976-89-3)

Rabeprazole, a partially reversible inhibitor of gastric proton pump, could be used in the treatment of sorts of gastrointestinal disease especially peptic ulce...

CAS 164579-32-2 Pantoprazole sodium hydrate

Pantoprazole sodium hydrate
(CAS: 164579-32-2)

Pantoprazole sodium hydrate is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or amel...

CAS 73590-58-6 Omeprazole

Omeprazole
(CAS: 73590-58-6)

Omeprazole is a proton pump inhibitor used in the treatment of dyspepsia. It binds to the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase)...

CAS 335299-59-7 Tenatoprazole sodium

Tenatoprazole sodium
(CAS: 335299-59-7)

Tenatoprazole is a novel proton pump inhibitor which is similar to the chemical structure of omeprazole, a widely used proton pump inhibitor. Tenatoprazole belo...

CAS 261944-46-1 Soraprazan

Soraprazan
(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

Chemical Structure

CAS 73590-58-6 Omeprazole

Quick Inquiry

Verification code

Featured Items